Cargando...

Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose

BACKGROUND: In the era of molecularly targeted agents (MTAs), it is recommended to account for toxicity over several cycles to identify the recommended phase II dose (RP2D). We investigated the relationship between the risk of toxicity at cycle 1 and the cumulative incidence of toxicity over subsequ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Natl Cancer Inst
Autores principales: Altzerinakou, Maria-Athina, Collette, Laurence, Paoletti, Xavier
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6855968/
https://ncbi.nlm.nih.gov/pubmed/30838405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz024
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!